

Exportin 1 - Drugs In Development, 2021

<https://marketpublishers.com/r/E8A152C02A6DEN.html>

Date: June 2021

Pages: 143

Price: US\$ 3,500.00 (Single User License)

ID: E8A152C02A6DEN

Abstracts

Exportin 1 - Drugs In Development, 2021

SUMMARY

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) pipeline Target constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies. The latest report Exportin 1 - Drugs In Development, 2021, outlays comprehensive information on the Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Exportin 1 (XPO1) or chromosomal maintenance 1 (CRM1) is a eukaryotic protein. It mediates the nuclear export of cellular proteins bearing a leucine-rich nuclear export signal (NES) and of RNAs. In association with RANBP3, it binds cooperatively to the NES on its target protein and to the GTPase RAN in its active Ran-GTP. Docking of this complex to the nuclear pore complex (NPC) is mediated through binding to nucleoporins. It is involved in U3 snoRNA transport from Cajal bodies to nucleoli. The molecules developed by companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 3, 1, 3 and 1 respectively.

Report covers products from therapy areas Oncology, Central Nervous System, Immunology, Genetic Disorders and Infectious Disease which include indications Diffuse Large B-Cell Lymphoma, Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Colorectal Cancer, Multiple Myeloma (Kahler Disease), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Glioblastoma Multiforme (GBM),

Hematological Tumor, Metastatic Colorectal Cancer, Myelodysplastic Syndrome, Myelofibrosis, Non-Small Cell Lung Cancer, Prostate Cancer, Soft Tissue Sarcoma, Systemic Lupus Erythematosus, Triple-Negative Breast Cancer (TNBC), Adenocarcinoma, Amyotrophic Lateral Sclerosis, Anaplastic Large Cell Lymphoma (ALCL), Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Bone Sarcoma, Breast Cancer, Burkitt Lymphoma, Cervical Cancer, Chondrosarcoma, Coronavirus Disease 2019 (COVID-19), Cytomegalovirus (HHV-5) Infections, Dedifferentiated Liposarcoma, Duchenne Muscular Dystrophy, Endometrial Cancer, Epstein-Barr Virus (HHV-4) Infections, Ewing Sarcoma, Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma), Fallopian Tube Cancer, Follicular Lymphoma, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Tumor, High-Grade Glioma, Human Immunodeficiency Virus (HIV) Infections (AIDS), Leiomyosarcoma, Liposarcoma, Malignant Mesothelioma, Mantle Cell Lymphoma, Melanoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Multiple Sclerosis, Natural Killer Cell Lymphomas, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Neuroendocrine Tumors, Ovarian Cancer, Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Peripheral T-Cell Lymphomas (PTCL), Peritoneal Cancer, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Post-Transplant Lymphoproliferative Disorder, Primary Mediastinal B-Cell Lymphoma, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Acute Myeloid Leukemia, Relapsed Chronic Lymphocytic Leukemia (CLL), Respiratory Syncytial Virus (RSV) Infections, Rheumatoid Arthritis, Small-Cell Lung Cancer, Spinal Cord Injury, Synovial Sarcoma, Thymoma (Thymic Epithelial Tumor), Traumatic Brain Injury, Unspecified Influenza Virus Infections, Urinary Tract Cancer and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

Furthermore, this report also reviews key players involved in Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1)

The report reviews Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics and enlists all their major and minor projects

The report assesses Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Overview

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) -

Therapeutics Development

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) -

Therapeutics Assessment

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) -

Companies Involved in Therapeutics Development

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Drug
Profiles

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Dormant
Products

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) -

Discontinued Products

Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) - Product
Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indications, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Biogen Inc, 2021

Pipeline by CanBas Co Ltd, 2021

Pipeline by Jiangsu Carephar Pharmaceutical Co Ltd, 2021

Pipeline by Karyopharm Therapeutics Inc, 2021

Pipeline by Oita University Institute of Advanced Medicine Inc, 2021

Pipeline by Wigen Biomedicine Technology (Shanghai) Co Ltd, 2021

Dormant Products, 2021

Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

I would like to order

Product name: Exportin 1 - Drugs In Development, 2021

Product link: <https://marketpublishers.com/r/E8A152C02A6DEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E8A152C02A6DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970